Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2009-011520-53 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to non-biologic DMARDs. Patients will receive tocilizumab 8 mg/kg as intravenous infusion once every 4 weeks in combination with methotrexate or in case of intolerance to methotrexate as monotherapy. The anticipated time of study treatment is 6 months. The target sample size is 20-50 patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Arm | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| tocilizumab [RoActemra/Actemra] | Drug | tocilizumab 8 mg/kg intravenous infusion once in 4 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Adherent to Original Treatment | Adherence rate to original treatment according to the protocol included all participants that received the study drug beginning from Week 8 and remaining until the end of the study. This number represents participants with no changes in treatment protocol, participants with treatment discontinuation, and participants with dose reduction, but not participants that withdrew from the study prematurely. | Week 24 |
| Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason | Weeks 0, 4, 8, 12, 16, 20, and 24 | |
| Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason | Weeks 0, 4, 8, 12, 16, 20, and 24 | |
| Percentage of Participants Withdrawing From the Study Prematurely for Any Reason | Weeks 0, 4, 8, 12, 16, 20, and 24 | |
| Percentage of Participants With Dose Reduction to Tocilizumab 4 mg/kg | Weeks 0, 4, 8, 12, 16, and 20 |
| Measure | Description | Time Frame |
|---|---|---|
| Disease Activity Score Based on 28-Joint Count (DAS28) | DAS28 calculated from the number of swollen joints and tender joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Piešťany | 921 12 | Slovakia |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Tocilizumab 8 Milligrams Per Kilogram (mg/kg) | Participants received tocilizumab 8 mg/kg intravenously (IV) once every 4 weeks for a maximum of 20 weeks (total of 6 infusions). |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
All participants who received at least one dose of study drug.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Tocilizumab 8 mg/kg | Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants Adherent to Original Treatment | Adherence rate to original treatment according to the protocol included all participants that received the study drug beginning from Week 8 and remaining until the end of the study. This number represents participants with no changes in treatment protocol, participants with treatment discontinuation, and participants with dose reduction, but not participants that withdrew from the study prematurely. | Intent-to-treat population (ITT), all enrolled participants who received at least one dose of study drug | Posted | Number | percentage of participants | Week 24 |
|
Serious adverse events (SAEs) related to study medication were reported irrespective of elapsed time from last administration of study medication. Non-related SAEs were reported during the study period and 28 days after the last dose of study medication.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Tocilizumab 8 mg/kg | Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions). |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Crash of left foot local infection of skin and subcutaneous tissue | Infections and infestations | MedDRA (10.0) | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hepatopathy | Hepatobiliary disorders | MedDRA (10.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Communications | Hoffmann- LaRoche. | 800-821-8590 | genentech@druginfo.com |
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C502936 | tocilizumab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Weeks 0, 4, 12, and 24 |
| Patient Global Assessment of Pain | Participants were asked to rate their pain using a 0 to 100 mm visual analog scale (VAS), where 0 mm = no pain and 100 mm = worst possible pain. The participant was asked to mark the line corresponding to their perceived level of pain and the distance in mm from the left edge of the scale was measured. | Weeks 0, 4, 8, 12, 16, 20, and 24 |
| Patient Global Assessment of Disease Activity | The participant's assessment of disease activity was performed using a 100 mm VAS ranging from no activity (0) to maximal activity (100). The participant was asked to mark the line corresponding to their perceived level of disease activity and the distance in mm from the left edge of the scale was measured. | Weeks 0, 4, 8, 12, 16, 20, and 24 |
| Physician's Global Assessment of Disease Activity | Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The physician was asked to mark the line corresponding to their perceived level of the participant's disease activity and the distance in mm from the left edge of the scale was measured. | Weeks 0, 4, 8, 12, 16, 20, and 24 |
| Swollen Joint Count (SJC) | The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not swollen or 1=swollen. The total number was calculated from all the joints for a maximum score of 28. | Weeks 0, 4, 8, 12, 16, 20, and 24 |
| Tender Joint Count (TJC) | The following 28 joints were assessed by the physician for tenderness: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not tender or 1=tender. The total number was calculated from all the joints for a maximum score of 28. | Weeks 0, 4, 8, 12, 16, 20, and 24 |
| Erythrocyte Sedimentation Rate (ESR) | ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. | Weeks 0, 4, 12, 20, and 24 |
| C-Reactive Protein (CRP) | CRP is an acute phase protein. Levels of CRP increase with inflammation. | Weeks 0, 4, 12, 20, and 24 |
| Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. | Weeks 0, 4, 8, 12, 16, 20, and 24 |
| Short Form-36 (SF-36) | The SF-36 measures the impact of disease on overall quality of life and consists of 8 subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health. | Weeks 0, 12, and 24 |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Disease Duration | Mean | Standard Deviation | years |
|
| Disease Phase/Stage | Disease stages/phases of rheumatoid arthritis (RA): Stage I represents synovitis: synovial membrane becomes hyperemic and edematous; joint effusions with high cell count; x-rays will as yet show no destructive changes, but soft tissue swelling or osteoporosis may be seen; Stage II: inflamed synovial tissue now proliferates and begins to grow into joint cavity across articular cartilage, which it gradually destroys; Stage III: pannus of synovium; eroded articular cartilage and exposed subchondral bone x-rays will show extensive cartilage loss; Stage IV represents end-stage disease. | Number | participants |
|
| Functional Class of Disease | Classification of global functional status in RA is as follows: Class I: completely able to perform usual activities of daily living (self-care, vocational, and avocational); Class II: able to perform usual self-care and vocational activities, but limited in avocational activities; Class III: able to perform usual self-care activities, but limited in vocational and avocational activities; and Class IV: limited in ability to perform usual self-care, vocational, and avocational activities. | Number | participants |
|
| C-Reactive Protein (CRP) | CRP was measured in milligrams per liter (mg/L) | Mean | Standard Deviation | mg/L |
|
| Erythrocyte Sedimentation Rate (ESR) | ESR was measured in millimeters per hour (mm/hr) | Mean | Standard Deviation | mm/hr |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Secondary | Disease Activity Score Based on 28-Joint Count (DAS28) | DAS28 calculated from the number of swollen joints and tender joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | units on a scale | Weeks 0, 4, 12, and 24 |
|
|
|
| Primary | Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason | ITT Population | Posted | Number | percentage of participants | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Primary | Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason | ITT Population | Posted | Number | percentage of participants | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Primary | Percentage of Participants Withdrawing From the Study Prematurely for Any Reason | ITT Population | Posted | Number | percentage of participants | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Primary | Percentage of Participants With Dose Reduction to Tocilizumab 4 mg/kg | ITT Population | Posted | Number | percentage of participants | Weeks 0, 4, 8, 12, 16, and 20 |
|
|
|
| Secondary | Patient Global Assessment of Pain | Participants were asked to rate their pain using a 0 to 100 mm visual analog scale (VAS), where 0 mm = no pain and 100 mm = worst possible pain. The participant was asked to mark the line corresponding to their perceived level of pain and the distance in mm from the left edge of the scale was measured. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | units on a scale | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Secondary | Patient Global Assessment of Disease Activity | The participant's assessment of disease activity was performed using a 100 mm VAS ranging from no activity (0) to maximal activity (100). The participant was asked to mark the line corresponding to their perceived level of disease activity and the distance in mm from the left edge of the scale was measured. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | units on a scale | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Secondary | Physician's Global Assessment of Disease Activity | Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The physician was asked to mark the line corresponding to their perceived level of the participant's disease activity and the distance in mm from the left edge of the scale was measured. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | units on a scale | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Secondary | Swollen Joint Count (SJC) | The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not swollen or 1=swollen. The total number was calculated from all the joints for a maximum score of 28. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | swollen joints | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Secondary | Tender Joint Count (TJC) | The following 28 joints were assessed by the physician for tenderness: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not tender or 1=tender. The total number was calculated from all the joints for a maximum score of 28. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | tender joints | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Secondary | Erythrocyte Sedimentation Rate (ESR) | ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. | TT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | mm/hr | Weeks 0, 4, 12, 20, and 24 |
|
|
|
| Secondary | C-Reactive Protein (CRP) | CRP is an acute phase protein. Levels of CRP increase with inflammation. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | mg/L | Weeks 0, 4, 12, 20, and 24 |
|
|
|
| Secondary | Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | scores on a scale | Weeks 0, 4, 8, 12, 16, 20, and 24 |
|
|
|
| Secondary | Short Form-36 (SF-36) | The SF-36 measures the impact of disease on overall quality of life and consists of 8 subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health. | ITT population; n=number of participants assessed for the specified parameter at a given visit. | Posted | Mean | Standard Deviation | scores on a scale | Weeks 0, 12, and 24 |
|
|
|
| 3 |
| 32 |
| 10 |
| 32 |
| Bronchopneumonia | Infections and infestations | MedDRA (10.0) | Non-systematic Assessment |
|
| Lumbago | Musculoskeletal and connective tissue disorders | MedDRA (10.0) | Non-systematic Assessment |
|
| Congestive heart failure | Cardiac disorders | MedDRA (10.0) | Non-systematic Assessment |
|
| Leucopenia+lymphopenia | Blood and lymphatic system disorders | MedDRA (10.0) | Systematic Assessment |
|
| Acute bronchitis | Reproductive system and breast disorders | MedDRA (10.0) | Systematic Assessment |
|
| Acute nasopharyngitis | Respiratory, thoracic and mediastinal disorders | MedDRA (10.0) | Systematic Assessment |
|
| Acute pulpitis | Infections and infestations | MedDRA (10.0) | Systematic Assessment |
|
The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| Title | Measurements |
|---|---|
|
| Week 24 (n=30) |
|
| Title | Measurements |
|---|---|
|
| Week 12 (n=30) |
|
| Week 16 (n=30) |
|
| Week 20 (n=30) |
|
| Week 24 (n=30) |
|
| Title | Measurements |
|---|---|
|
| Week 12 (n=30) |
|
| Week 16 (n=30) |
|
| Week 20 (n=30) |
|
| Week 24 (n=30) |
|
| Title | Measurements |
|---|---|
|
| Week 12 (n=30) |
|
| Week 16 (n=30) |
|
| Week 20 (n=30) |
|
| Week 24 (n=30) |
|
| Title | Measurements |
|---|---|
|
| Week 12 (n=30) |
|
| Week 16 (n=30) |
|
| Week 20 (n=30) |
|
| Week 24 (n=30) |
|
| Title | Measurements |
|---|---|
|
| Week 12 (n=30) |
|
| Week 16 (n=30) |
|
| Week 20 (n=30) |
|
| Week 24 (n=30) |
|
| Title | Measurements |
|---|---|
|
| Week 20 (n=30) |
|
| Week 24 (n=30) |
|
| Title |
|---|
| Measurements |
|---|
|
| Week 20 (n=30) |
|
| Week 24 (n=30) |
|
| Title | Measurements |
|---|---|
|
| Week 12 (n=30) |
|
| Week 16 (n=30) |
|
| Week 20 (n=30) |
|
| Week 24 (n=30) |
|
|
| Role limits due to physical health, Week 0 (n=32) |
|
| Role limits due to physical health, Week 12 (n=30) |
|
| Role limits due to physical health, Week 24 (n=30) |
|
| Role limits due to emotional prob., Week 0 (n=32) |
|
| Role limits due to emotional prob., Week 12 (n=30) |
|
| Role limits due to emotional prob., Week 24 (n=30) |
|
| Energy/fatigue, Week 0 (n=32) |
|
| Energy/ fatigue, Week 12 (n=30) |
|
| Energy/fatigue, Week 24 (n=30) |
|
| Emotional well-being, Week 0 (n=32) |
|
| Emotional well-being, Week 12 (n=30) |
|
| Emotional well-being, Week 24 (n=30) |
|
| Social functioning, Week 0 (n=32) |
|
| Social functioning, Week 12 (n=30) |
|
| Social functioning, Week 24 (n=30) |
|
| Pain, Week 0 (n=32) |
|
| Pain, Week 12 (n=30) |
|
| Pain, Week 24 (n=30) |
|
| General health, Week 0 (n=32) |
|
| General health, Week 12 (n=30) |
|
| General health, Week 24 (n=30) |
|